News

The antibiotic dirithromycin (no longer available in the U.S.; sold in other countries under the brand name Dynabac) may be a potentially effective therapy for acute exacerbations in patients with chronic obstructive pulmonary disease (COPD), according to findings from a meta-analysis of antibiotics in clinical trials. Chinese researchers published…

GSK and Innoviva submitted new Phase 3 data to support label expansion of Trelegy Ellipta for European patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are at risk of an exacerbation and require triple therapy. The regulatory submission to the…

Using long-term inhaled corticosteroids to relieve inflammation in chronic obstructive pulmonary disease (COPD) could increase the risk of bone fractures, new research suggests. A study published in the journal CHEST, “Long-term Use of Inhaled Corticosteroids in COPD and the Risk of Fracture,” was conducted by researchers from McGill University…

COPD increases the risk of a person having additional health conditions and taking multiple medications, a British study shows. The research, “Examining patterns of multimorbidity, polypharmacy and risk of adverse drug reactions in chronic obstructive pulmonary disease: a cross-sectional UK Biobank study,” was published in the journal…

Vitamin D levels are associated with respiratory function and health, research from Australia shows. The findings suggest an additional process could be driving diseases such as chronic obstructive respiratory disease (COPD). The study, “Vitamin D and respiratory health in the Busselton Healthy Ageing Study,” was published…

The U.S. Food and Drug Administration (FDA) accepted for review a New Drug Application (NDA) submitted by Theravance Biopharma and Mylan for their collaborative compound revefenacin (TD-4208), a bronchodilator for the treatment of chronic obstructive pulmonary disease (COPD) in adults. The two pharmaceutical companies are aiming to develop and…

AstraZeneca’s Daliresp (roflumilast) is now approved at 250 micrograms (mcg) for the first four weeks followed by 500 mcg thereafter to treat patients with chronic obstructive pulmonary disease (COPD). This approval by the U.S. Food and Drug Administration (FDA) will help reduce the rate of discontinuation previously reported in patients…

Better and more adequate home-based care for patients with chronic obstructive pulmonary disease (COPD) can significantly improve their quality of life and reduce the need of hospital-based treatments. This finding was reported by the Canadian Foundation for Healthcare Improvement (CFHI) as a result of its INSPIRED initiative,…

Variations in the anatomy of airway branches may be used as indicators for people at higher risk of developing chronic obstructive pulmonary disease (COPD), a new study found. The team of researchers, funded by the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH), discovered…

A new class of kinase inhibitors shows promising anti-inflammatory effects in airway cells of patients with chronic obstructive pulmonary disease (COPD), according to a collaborative research study. The study, “Superior anti-inflammatory effects of narrow-spectrum kinase inhibitors in airway smooth muscle cells from subjects with chronic obstructive…